Use of a custom next-generation sequencing assay may accurately predict mismatch repair deficiency on the basis of mutational load in colorectal cancer, according to a report by Stadler et al in the Journal of Clinical Oncology. Study Details The study involved data from 224 patients with...
Researchers at the University of Southern California (USC) Norris Comprehensive Cancer Center of Keck Medicine of USC and Clalit National Israel Cancer Control Center have found that coffee consumption may be inversely associated with the risk of colorectal cancer. The findings by Schmit et...
Christopher Willett, MD, of Duke Cancer Center, discusses short and long courses of treatment, neoadjuvant chemotherapy with or without radiation, and organ preservation without surgery.
Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.
Using the latest advances in endoscopic resection techniques, more than 75% of patients with complex colon polyps could avoid surgery for their polyp removal, according to new research from The University of Texas MD Anderson Cancer Center. The findings, published by Raju et al in Gastrointestinal ...
Treatment with low-dose metformin reduced the risk of metachronous colorectal adenomas and polyps over 12 months in nondiabetic patients who had undergone endoscopic polypectomy, according to a report by Higurashi et al in The Lancet Oncology. Study Details In the double-blind phase III trial,...
Increased travel distance to a cancer treatment facility negatively impacts the likelihood that patients with stage II/III rectal cancer will receive radiation therapy to treat their disease, according to a study analyzing 26,845 patient records from the National Cancer Data Base (NCDB) published...
In an analysis of the PETACC-8 trial reported by Taieb et al in JAMA Oncology, BRAF V600 and KRAS mutations were associated with shorter disease-free and overall survival in patients with microsatellite-stable colon cancer—but not in those with tumors with microsatellite instability—in...
In a long-term follow up of two large U.S. prospective cohorts reported in JAMA Oncology, Cao et al found that regular use of aspirin was associated with a reduced risk of gastrointestinal (GI) tract cancers. In 2015, the U.S. Preventive Services Task Force recommended the use of aspirin in...
A study published by Beyaz et al in Nature reveals how a high-fat diet makes the cells of the intestinal lining more likely to become cancerous. It joins a growing body of research that finds obesity and eating a high-fat, high-calorie diet are significant risk factors for many types of cancer....
In the UK phase III PICCOLO trial reported in JAMA Oncology, Seligmann et al found that high expression of either of the epidermal growth factor receptor (EGFR) ligands epiregulin or amphiregulin was associated with a progression-free survival benefit with panitumumab (Vectibix)/irinotecan vs...
Stock your practice with Cancer.Net resources. Cancer.Net has a comprehensive guide to colorectal cancer at www.cancer.net/colorectal and a shorter, one-page colorectal cancer fact sheet. You will also find specialized resources for caregiving, survivorship, palliative care, and managing the cost...
A study published by Bradley et al in Medical Care showed that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2% to 53%. During this period, 1-year treatment costs increased 32% to reach an...
In the phase III SIRFLOX trial reported in the Journal of Clinical Oncology, van Hazel et al found that adding selective internal radiation therapy with yttrium-90 resin microspheres to FOLFOX (fluorouracil, leucovorin, oxaliplatin) with or without bevacizumab (Avastin) did not improve any-site...
In a retrospective case-controlled study conducted in patients with colorectal cancer who had received primary tumor resection with or without preoperative radiofrequency ablation for liver metastases, the electrical procedure was found to induce antitumor immune responses in the...
In an analysis of the ACCENT (Adjuvant Colon Cancer Endpoints) database reported in the Journal of Clinical Oncology, Cheung et al found that factors associated with early mortality in patients in trials of adjuvant systemic therapy included age, performance status, tumor grade, stage, and ratio of ...
Annual screening with the fecal immunochemical test is highly sensitive for detecting colorectal cancer and “is feasible and effective for population-level colorectal cancer screening,” according to a large-scale retrospective cohort study assessing the fecal immunochemical...
According to new recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer published by Kahi et al in Gastroenterology, postoperative colonoscopy is associated with improved overall survival for colorectal cancer patients. Therefore, it is critically important that colorectal...
In a study reported in The New England Journal of Medicine, Dalerba et al found that absence of the transcription factor CDX2, although prognostic for poor outcome in stage II and III colon cancer vs cancers with CDX2 expression, identified a subgroup of high-risk patients who appeared to benefit...
Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.
Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).
Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).
Chloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco, talks with Axel Grothey, MD, of the Mayo Clinic, about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic...
John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Martine Frouws, MD, PhD Candidate, of Leiden University Medical Centre discusses her study, which showed a significant increase in overall survival among patients with GI cancers who took aspirin compared to those who did not (Abstract 2306).
Michel Ducreux, MD, PhD, of the Institut Gustave Roussy, discusses the efficacy and safety in this study of nab-paclitaxel in patients with previously treated metastatic colorectal cancer (Abstract 2131).
Leonard Gunderson, MD, of the Mayo Clinic College of Medicine, discusses PET/CT imaging in upper and lower gastrointestinal cancers, which can be of value as a baseline study prior to treatment, in determining the degree of response to treatment, and in helping decide whether there is a relapse...
Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses in German the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patients with metastatic colorectal cancer (Abstract 493).
Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patients with metastatic colorectal cancer (Abstract 493). To view the German language version of this...
Krzysztof Bujko, MD, of the Maria Skłodowska Curie Memorial Cancer Centre, discusses the results of a multicenter Polish study on neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer (Abstract 489).
Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses in French the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490).
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490). To view the French language version of this newsreel, click here.
All National Cancer Institute (NCI)-designated cancer centers have united to support human papillomavirus (HPV) vaccination. A team of HPV experts drafted a consensus statement that advises widespread use of HPV vaccines to prevent cancer. HPV causes cancer of the cervix, anus, and throat. The HPV ...
Nearly 15% of patients diagnosed with colorectal cancer were younger than 50, the age at which screening recommendations begin. The study by researchers at the University of Michigan Comprehensive Cancer Center also found that younger patients were more likely to have advanced disease. The authors ...
Although the fecal immunochemical test is a common method for colorectal cancer screening, its acceptability and performance over several rounds of annual testing are largely unknown. Now, a large retrospective cohort study by Jensen et al assessing the fecal immunochemical...
Solid-organ transplant recipients have a higher rate of cancer mortality than what is expected in the general population, according to a Canadian study by Acuna et al published in JAMA Oncology. Cancer mortality among transplant recipients was significantly elevated compared with data for the...
Obesity has long been associated with increased risk of colorectal cancer, but the link has never been understood. Now, a research team led by investigators at Thomas Jefferson University has revealed the biologic connection, and in the process, has identified an approved drug that might prevent...
Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact...
March is Colorectal Cancer Awareness Month, and the U.S. Department of Health and Human Services is committed to boosting public awareness about the importance of screening and treatment for colorectal cancer. Colorectal cancer poses the greatest risk to adults over age 50, and the U.S. Preventive...
Researchers at Roswell Park Cancer Institute have been awarded three of four grants by the National Comprehensive Cancer Network (NCCN) Oncology Research Program to evaluate and define the clinical effectiveness of the investigational compound nintedanib. Nintedanib is an investigational...
ASCO is among the medical professional societies supporting the National Colorectal Cancer Roundtable (NCCRT) by recruiting physician leaders from within its membership for a pilot program called Links of Care. The program was established to promote health equity and to improve access to colorectal ...
"Nobody tells a 28 year old to get a colonoscopy.” It’s the sad but true reality that many young adults may be at risk for colorectal cancer. Unfortunately, many people, young adults in particular, are not aware of the risk factors and do not get screened early enough to catch the disease when it...
Stock your practice with Cancer.Net resources. Cancer.Net has a comprehensive guide to colorectal cancer at www.cancer.net/colorectal and a shorter, one-page colorectal cancer fact sheet. You will also find specialized resources for survivorship, palliative care, and managing the cost of cancer...
The recently updated ASCO Answers: Guide to Colorectal Cancer helps people who are newly diagnosed better understand the disease and their treatment options. This information-packed guide includes treatment information; an emphasis on palliative care; an expanded follow-up care section; questions...
A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer, University of Missouri (MU) School of Medicine researchers have found. It is a finding that may lay the foundation for new colorectal cancer treatments. Results ...
Follow-up times of abnormal screening exams were shorter for breast cancer than they were for colorectal and cervical cancers, according to a recent study involving more than 1 million individuals who underwent these screenings. Recently published by Tosteson et al in the Journal of General...
As reported by Murphy et al in the Journal of the National Cancer Institute, an analysis of Surveillance, Epidemiology, and End Results (SEER) data from patients with stage II or III colorectal cancer indicated that the use of adjuvant chemotherapy in colon cancer declined slightly between 2005 and ...
In the first study of its kind, University of Southern California (USC) researchers have found that colorectal cancer risk in Californian Latinos varies widely depending on the country of origin. Their study was published by Stern et al in Cancer Causes & Control. “Hispanics are a very...
In a nested case-control study in the Women’s Health Initiative Clinical Trial, reported in Journal of the National Cancer Institute by Murphy et al, endogenous estrogen levels were inversely associated with and sex hormone–binding globulin (SHBG) levels were positively associated with...